Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2876 - Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine


08 Oct 2016


Poster Display


Jole Ventriglia


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


J. Ventriglia1, A. Petrillo1, M. Huerta2, M.M. Laterza1, B. Savastano1, V. Gambardella2, G. Tirino1, L. Pompella1, A. Diana1, A. Febbraro3, T. Troiani1, M. Orditura1, A. Cervantes2, F. Ciardiello1, F. De Vita1

Author affiliations

  • 1 Medical Oncology, AOU Seconda Università degli Studi di Napoli (AOU-SUN), 80130 - Napoli/IT
  • 2 Medical Oncology, Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 3 Medical Oncology, Ospedale "Sacro Cuore di Gesù" Fatebenefratelli, Benevento/IT


Abstract 2876


High neutrophil to lymphocyte ratio (NLR) can be a predictor of poor outcomes in various malignancies, including pancreatic cancer (PC). Based on these data, we investigated NLR as prognostic markers in MPC pts who received first-line chemotherapy with nab-paclitaxel/gemcitabine; furthermore a prognostic model using inflammatory-based scores to predict survival was planned.


We assessed 70 pts with histologically confirmed MPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different European oncologic centres between January 2012 and November 2015. The cut-off for the NLR was 5. Variables assessed for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level ≥ 59xULN, 12-week decrease of CA19.9 level ≥ 50% from baseline, basal bilirubin level, baseline neutrophil to lymphocyte ratio, biliary stent implantation and liver metastasis. Survival analyses were generated according to the Kaplan-Meier method. Univariate and multivariate analyses were performed by Cox proportional hazard model.


With a median follow up of 32 months, median PFS and OS were 7.0 months (95% C.I. 6.221 – 7.779) and 12 months (95% C.I. 9.926-14.074), respectively with a 12-month OS rate of 34.3%. According to NLR values, the patients were divided into two groups. Median PFS and OS were 5 months and 7 months (p= 0.02) and 7 months and 13 months (p= 0.003) in high (NLR ≥ 5) and low (NLR


Baseline NLR is an indipendent predictor of survival of patients with MPC receiving palliative chemotherapy and could be useful to develop a simple clinical score to identify a subgroup of patients with a low chance to benefit from chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Second University of Naples


Second University of Naples


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings